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Background: Regulatory and health technology assessment agencies have commented differently on the question
whether results from enrichment studies can be used to justify to bring a test into use. We try to provide a framework
to discuss this issue.
Results: Mathematical definitions for the value and the benefit of a new diagnostic test are given. The possible
conclusions about value and benefit from enrichment studies and interaction studies are explored. The terms
benefit-based strategy and value-based strategy are introduced. Several potential consequences of using one of the
two strategies in deciding to bring a test into use are identified and quantified. Interaction designs allow to assess
benefit and value. Enrichment designs allow only to assess benefit. However, it is often probable that interaction
studies allow no firm conclusions about the value. The advantage of a benefit-based strategy stems mainly from
allowing test-positive patients earlier or even ever to benefit. The main disadvantage is a potential delay in detecting
tests of no value.
Conclusions: Benefit-based strategies are preferable if the risk of off-label use and of delayed decisions on the value
of a test can be limited. Otherwise, the superiority depends highly on research practice.
Keywords: Benefit, Biomarker, Diagnostic test, Enrichment designs, Interaction designs
Background
In developing new diagnostic tests and assessing their
benefit for patients, enrichment designs are one popu-
lar design. In enrichment designs, only the test-positive
patients are randomized to the two treatments of inter-
est, typically the standard treatment currently given to all
patients and a new treatment expected to improve patient
outcomes in test-positive patients. Consequently, we can
at the best only conclude that the new treatment is ben-
eficial for test-positive patients. It may happen that other
studies randomizing (also) test-negative patients demon-
strate (later) that also the test-negative patients benefit
from the new treatment. Then, there is actually no need
for the test: We can improve patient outcomes just by
giving the new treatment to all patients. In other words,
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the test is only of value, if it is justified to withhold
treatment in test-negative patients [1].
This potential constellation raises the question about
adequate conclusions about a new diagnostic test when
only results from an enrichment study are available. Sev-
eral regulatory or health technology assessment agen-
cies already commented on this question. The FDA [2]
expressed the wish that “. . . ideally . . . there will be at
least some data on the marker negative population. . . ”.
The EMA [3] expressed its concerns by stating that “The
regulatory acceptability of excluding. . . negative patients
from trials will depend on the strength of evidence (plau-
sibility, scientific rationale and clinical data) provides
for the lack of effect in these patients.” The German
IQWiG [4] simply concludes about enrichment designs
that “. . . such designs allow conclusions only if other infor-
mation allows to exclude that an effect observed in the
randomized patients would also be present in the non-
randomized patients1.” The FDA already pointed out a
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potential undesirable consequence of such a rigorous
approach: “When the treatment is a critical advance for
the enriched group, it would generally be unreasonable
to delay approval for the enriched group, even if few
data on the group without the enrichment factor were
available . . . ”.
To clarify the impact of such differences in the inter-
pretation of results from enrichment designs, we contrast
in this paper the benefit of a new test—i.e., the improve-
ment in outcome—with the value of the new test—i.e.,
whether the test can be used to justify different treatment
decisions in two groups of patients. We first introduce
formal definitions of these two concepts. Next, we dis-
cuss conclusions we can draw about the value or the
benefit of a new diagnostic test from results of random-
ized diagnostic studies following one of the three most
common designs: interaction studies, enrichment studies,
and comparative studies. Then, we consider two gen-
eral strategies to make decisions about bringing a test
into use, reflecting the abovementioned differences in the
interpretation. We distinguish between value-based and
benefit-based strategies and present several issues we have
to take into account if we want to identify the better
strategy.
Methods
In the following, we assume that a diagnostic test T is
applied in the patient population of interest. The test
yields a positive test result with probability pT+ and a neg-
ative test result with probability pT− := 1 − pT+. The
test should inform the choice between two interventions,
which we denote by i+ and i−.We expect that test-positive
patients benefit from i+ compared to i−, but that this does
not hold for the test-negative patients. If we randomize
patients to i+ or i−, we would observe in test-positive
patients the treatment effect θT+ := E(Y |T = +, I =
i+) − E(Y |T = +, I = i−) and in test-negative patients
the treatment effect θT− := E(Y |T = −, I = i+) −
E(Y |T = −, I = i−). The random variable Y denotes here
a patient-relevant outcome with large values represent-
ing a more favorable outcome. It may be measured on a
binary, continuous, count, or time to event scale. We fur-
ther assume that i+ represents an experimental treatment
in the sense that we would prefer to choose i− instead of
i+ when we are forced to make a uniform choice for all
patients.
In discussing the value of a diagnostic test, we are com-
paring three patient management strategies: giving i− to
both test-positive patients and test-negative patients (as
we would do if the diagnostic test is not available), giv-
ing i+ to test-positive patients and i− to test-negative
patients, and giving i+ to both test-positive and test-
negative patients. Each strategy implies a corresponding
level of the average outcome:
e−− := E(Y |I = i−,T = +)P(T = +)
+E(Y |I = i−,T = −)P(T = −) = E(Y |I = i−)
eT+− := E(Y |I = i+,T = +)P(T = +)
+E(Y |I = i−,T = −)P(T = −)
e++ := E(Y |I = i+,T = +)P(T = +)
+E(Y |I = i+,T = −)P(T = −) = E(Y |I = i+)
The difference between eT+− and e−− reflects the benefit
we expect from applying the test: We hope to be able to
improve the average outcome by giving the test-positive
patients the better treatment i+. Indeed, we have for this
benefit bT the simple relation
bT := eT+− − e−− = E(Y |I = i+,T = +)P(T = +)
+E(Y |I = i−,T = −)P(T = −) − E(Y |I = i−)
= E(Y |I = i+,T = +)P(T = +)
+E(Y |I = i−,T = −)P(T = −)
− (E(Y |I = i−,T = +)P(T = +)
+E(Y |I = i−,T = −)P(T = −))
= E(Y |I = i+,T = +)P(T = +)
−E(Y |I = i−,T = +)P(T = +)
= θT+pT+
i.e., the benefit is positive if θT+ is positive.
However, we cannot exclude that it is actually best to
give i+ to all patients, i.e., that e++ is also larger than eT+−.
This is actually the case if θT− is positive, as we have the
simple relation e++−eT+− = θT−pT−. Hence, the test is of no
value if both θT− and θT+ are positive (or both are negative),
as then it is optimal to give i+ to all patients (or i− to all
patients, respectively), and we cannot improve the average
outcome by applying the diagnostic test. Only if θT− ≤ 0
and θT+ > 0 the test is of value, as its application allows us
to achieve the optimal average outcome eT+−.
If there exists already a diagnostic test T1 to inform the
choice between i+ and i−, and if we want to demonstrate
that it is useful to replace T1 by T2, we have to show
that we further improve the average outcome by using T2
instead of T1, i.e., that eT2+− > e
T1+−. By the definition of bT ,
this is equivalent to bT2 > bT1 . Hence, we have to demon-
strate that T2 implies a larger benefit. However, this does
not immediately imply thatT2 is of value, as θT2− > 0 is still
possible. Only if T1 is of value, then we can conclude that










So, if we improve the benefit when using T2 instead of
T1, we increase θT+pT+, and hence, we decrease θT−pT−, as
the sum remains constant. Consequently, if θT1− is non-
positive, θT2− must be non-positive, too.
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Our definition of the benefit coincides with that given
for the benefit from a new biomarker by different authors
[5–8]. It should be distinguished from concepts like deci-
sion curve analysis and net benefit [9, 10]. These con-
cepts rely on the availability of a reference standard and
describe certain aspects of the accuracy of a test. How-
ever, knowledge about θT+ and θT− may be useful to define
the weights for false-negative or false-positive decisions
required within such concepts. For the case of paired
diagnostic studies, this idea has been exemplified in [11].
Results
Enrichment designs
In studies following an enrichment design [12] (also called
targeted or selection design), we first apply the diagnostic
test T in all patients in the population of interest. Patients
with a positive test result are then randomized to either
i+ or i−, and the outcome Y is only measured in these
patients. Consequently, in an enrichment design, we can
estimate θT+ from this subpopulation. To demonstrate that
there is a benefit from the test, it suffices to demonstrate
θT+ > 0. This can be approached by performing a standard
hypothesis test on H0 : θT+ ≤ 0.
Obviously, we cannot estimate θT− from an enrichment
design because in test-negative patients, the outcome Y
is not measured. Hence, in general, we cannot make any
conclusion about the value of the test. Exceptions may
occur, if it is impossible to apply the treatment i+ in test-
negative patients, e.g., if the test is detecting lesions which
have to be treated. A controversial point, however, will
often be that the choice of an enrichment design is based
on the expectation that the treatment i+ does not work
in the test-negative patients due to the underlying biolog-
ical or clinical model. However, such an expectation is no
empirical proof.
Interaction designs
In interaction designs, both test-positive as well as test-
negative patients are randomized to i+ and i−. Conse-
quently, we can estimate both θT+ and θT− , and we can
perform corresponding inference. A benefit can be proven
as above by demonstrating θT+ > 0. To demonstrate that
the test has a value, we have in addition to demonstrate
θT− ≤ 0. In analogy, we can approach this by performing a
test of H0 : θT− > 0. However, we are now confronted with
the challenge that this test may have very low power: Even
if the test T has no value, the true value of θT− may be close
to or exactly 0. Consequently, we may be willing to accept
that we cannot prove θT− ≤ 0, but only θT− ≤ θM, where
θM is an appropriately chosen margin. This margin should
reflect that even if θT− is above 0, but still below θM, we
would prefer to use i− instead of i+ in the test-negative
patients, for example, because of safety concerns about i+.
However, typically, this still implies that we need many
more test-negative patients than test-positive patients to
come to a decision about the value. To power the test for
H0 : θT− > θM, we will consider θT− = 0 as the rele-
vant alternative. To power the test forH0 : θT+ ≤ 0, we will
assume an effect θA in the test-positive patients which is
typically distinctly larger than θM. For example, if θM is
one third of θA, then we need approximately nine times
more test-negative patients than test-positive patients to
reach the same power. So, the feasibility of this approach is
highly depending on whether we have a sufficient number
of test-negative patients. The setting of the JUPITER study
[13] may serve as an example where such an approachmay
be feasible [14].
Instead of trying to demonstrate that the test has a value
on top of a proven benefit, we may alternatively try to
demonstrate that the test has no value, as this would allow
us to omit the test in the future. Here, we have to demon-
strate θT− > 0, which we can approach by testing H0 :
θT− ≤ 0. Again, we may be confronted with the challenge
of limited power, as even if θT− is above 0, it will be often
smaller than the effect in the test-positive patients. Mov-
ing to demonstrate θT− > θ˜M for some-negative margin θ˜M
is here not a convincing alternative as it is hard to justify
to recommend i+ to test-negative patients if it is slightly
worse than i−.
In reflecting about whether we have the power to make
a statement about the value of the test, it might be use-
ful to remember that most diagnostic tests are based on
dichotomizing a continuous (bio-)marker X at some pre-
specified cut point c. Then, we can consider the treatment
effect as a function of X, i.e.,
θ(x) = E(Y |I= i+,X = x) − E(Y |I= i−,X = x)
and we have θT+ = E(θ(X)|X > c) and θT− = E(θ(X)|X
< c). We can now consider two specific situations, which
may be often met in practice. In the first situation, i+ is
defined by an add-on to i−, such that we expect that all
patients still can benefit from i− if i+ is chosen, and the
test-positive patients may have an additional benefit by
the add-on. So it is reasonable to assume that θ(x) is pos-
itive or at least above a negative value close to 0 in the
majority of test-negative patients and only of substantial
magnitude close to the cut point. Consequently, θT− is also
close to 0, and we have to expect difficulties in proving
that the test has no value as well as that it has a value. A
second situation is given when i+ is a complete replace-
ment of i−, so we cannot expect a benefit by giving i+
when X is small. This means we have θ(x) < 0 for x below
a cutpoint c˜, and θ(x) is distinctly below 0 for the majority
of patients below this cutpoint. If c and c˜ roughly coin-
cide, we have θT− < 0 and probably distinctly below 0, and
hence, we have sufficient power to demonstrate that the
test has a value. On the other side, we must be aware of
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that even if the test has a value, it might be still suboptimal
in a case where c and c˜ differ substantially.
Two further remarks are necessary at this step. First,
even if we ask both the question whether the test is of
value (and accept the margin approach) and whether it
is of no value, we may fail to come to a definite conclu-
sion: Both the test on H0 : θT− > θM and the test on
H0 : θT− ≤ 0 can be insignificant. Actually, this is what we
have to expect for a diagnostic test T with θT− between 0
and θM (and slightly above and below this range) as then
both tests lack power. Second, our considerations about
analyzing interaction studies are different from what you
can find in the clinically oriented literature [15–17]. There
the emphasis is on demonstrating θT+ > 0 in the first place
and θT− > 0 in the second place, but not in demon-
strating θT− ≤ 0, as the latter has no implications on
treatment choice. Furthermore, there is also interest in
the overall treatment effect θall = e++ − e−−, in par-
ticular to demonstrate θall > 0, if the results allow to
demonstrate θT+ > 0 and support θT− > 0 without allowing
to demonstrate the latter. Consequently, studies follow-
ing an interaction design may require a new statistical
analysis independent of the analysis performed by the
principal investigator, if we want to make a decision about
the value of the test. As such an analysis involves up to
three null hypotheses (θT+ ≤ 0, θT− > θM, θT− < 0), an
adequate handling of multiplicity has to be planned. If the
results of the interaction study have been used to deter-
mine the cutpoint c, further statistical considerations are
necessary [8].
Actually, there are two different variants of interac-
tion designs. In randomize-all designs [18], all patients
are randomized and the test is applied in all patients. In
biomarker-stratified designs [19], the test is first applied
in all patients, and then in either the test-positive or the
test-negative patients, randomization is restricted to a
subsample, typically aiming at similar number of patients
in both groups. However, if the aim is to demonstrate the
value of the test, our considerations above suggest to aim
at more test-negative than test-positive patients in such
designs. The design has also an influence on estimating
pT+ in order to estimate the benefit. In the randomize all
designs, we can just use the randomized patients, whereas
in the biomarker stratified design, we have to make use of
all patients, not only the randomized ones.
Comparative randomized diagnostic studies
Comparative studies aim at comparing two diagnostic
tests T1 and T2. In randomized comparative diagnostic
studies, patients are randomized to either T = T1 or
T = T2, and only the corresponding test is applied in each
patient. The intervention i+ is applied in the case of a pos-
itive test result, and i− is applied in the case of a negative
test result. The outcome Y is measured in all patients. The
two arms can then be compared by looking at the differ-
ence in themean outcomes. This means we try to estimate
the effect
θ˜ := E(Y |T = T2) − E(Y |T = T1)
= E(Y |I = i+,T2 = +)P(T2 = +)
+E(Y |I = i−,T2 = −)P(T2 = −)
− (E(Y |I = i+,T1 = +)P(T1 = +)
+E(Y |I = i−,T1 = −)P(T1 = −))
= bT2 + E(Y |I = i−) − (bT1 + E(Y |I = i−))
= bT2 − bT1
i.e., the additional benefit.
Note that in this design, we do not randomize the treat-
ment. In test-positive patients, we always use i+, and in
test-negative patients, we always use i−. Hence, none of
the quantities θT1+ , θ
T2+ , θ
T1− , and θ
T2− are estimable. Conse-
quently, we cannot assess the value of T2 or T1. However,
as pointed out in the last section, if we demonstrate an
additional benefit of T2 and we already know that T1 is of
value, then we can conclude that T2 is of value, too.
The basic dilemma
Each country has today established a regulatory system
to control the process of bringing new drugs into use.
This process may include marketing approval, accessibil-
ity in a publicly financed health care system, or decisions
on reimbursement. In many countries, these systems are
also responsible for corresponding decisions on new diag-
nostic tests. For drugs, decisions are typically based on a
proof of an increased efficacy, i.e., improvements in out-
comes, together with considerations about safety or other
risks. Ignoring for a moment the latter and focusing on
efficacy, with respect to a diagnostic test, we are con-
fronted with the question whether we should require a
proof of the value of the test or a proof of the benefit of the
test.
There can be little doubt that from a societal perspec-
tive, it is desirable to bring only tests with a value into use.
Using a test with no value implies that we deny patients
with a negative test result to benefit from receiving i+
instead of i− and that the society has to spend resources
on applying the test T , although we can obtain even a
larger benefit just by giving i+ to all patients. However,
if the benefit of a test has been proven and we are still
lacking a proof of its value, insisting on such a proof has
a consequence which is not desirable: We deny patients
with a positive test result to benefit from i+ despite of a
proven benefit. This situation appears if a new diagnostic
test with no current competitor has been already success-
fully investigated in an enrichment design, but not (yet) in
an interaction design.
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Consequences of applying benefit-based and value-based
strategies for the decision on a single test
If we want to understand the advantages and disadvan-
tages of requiring a proof of the benefit or a proof of
the value, it is necessary to regard such decisions as part
of a general strategy applied to all new diagnostic tests:
The benefit-based strategy (BBS) requiring a proof of the
benefit and the value-based strategy (VBS) requiring a
proof of the value (which automatically implies a proof
of the benefit). In BBS, a test is brought into use when
we can demonstrate a benefit based on a study following
an enrichment design or a study following an interaction
design, which failed to come to a decision on the value.
We may later revise this decision in the sense to decide
to provide i+ to all patients and to stop using the test,
when we can demonstrate that the test is of no value. This
can be achieved by a study following an interaction design
or an randomized controlled trial (RCT) in test-negative
patients only. In VBS, there is only one decision at the
time point when the value or no value of the test has been
demonstrated. In the first case, the test is brought into
use and the test-positive patients receive i+, in the second
case, i+ is just given to all patients. Such a decision will be
typically based on a study with an interaction design, but it
is also possible to base it on separate RCTs in test-positive
and test-negative patients.
In Table 1, we illustrate some consequences of using
BBS or VBS using artificial study results from the develop-
ment of six different tests. We consider the case of one
study following an enrichment design and/or one (later)
study following an interaction design. For the first test,
the enrichment study demonstrated θT+ > 0 and in a
later interaction study, it could be demonstrated that θT−
is negative. Under BBS, the test would be in use after
the enrichment study and under VBS after the interaction
study. For the second test, the enrichment study demon-
strated the benefit, but the interaction study later revealed
that θT− is positive, i.e., the test is of no value. Under BBS,
the test would be in use in the time period between the
enrichment study and the interaction study, under VBS
never. For the third test, the enrichment study demon-
strated the benefit, but the interaction study remained
inconclusive with respect to the sign of θT− . Consequently,
under BBS, the test would be used after the enrichment
study, under VBS, it would be never used. For the fourth
test, only an enrichment design study was performed,
demonstrating θT+ > 0. Under BBS, the test would be used
after this study, under VBS, it would never be used. For the
fifth test, only an interaction design study was performed,
which demonstrated both θT+ > 0 as well as θT− < 0.
Under both strategies, the use of the test would start after
the study. For the sixth test, we have again only an interac-
tion study. This study demonstrated θT+ > 0, but remained
inconclusive with respect to θT− . Under BBS, the test would
come into use after the study, under VBS, it would never
come into use.
We now start with considering more generally the con-
sequences of following the two strategies on a single new
test T with θT+ > 0. Let tb denote the time point where the
benefit of the test is proven and tv the time point where the
value or no value of the test is proven, under the assump-
tion of following a VBS. Let  := tv − tb ≥ 0 denote the
duration where the test is not (yet) used in spite of having
a proof for the benefit (cf. Fig. 1). In the case of following
a BBS, we have to take into account that the time points
of obtaining a proof of the benefit or a proof of the value
or of no value may change. In particular, we may expect
that a proof of the benefit is obtained earlier—as the test
developers can bring the test into use by such a proof
and hence are more eager to conduct an enrichment study
early—and that a proof of the value is delayed—as the
test developers have no interest to stop the use of the test
and hence may hesitate to perform an interaction study
or an RCT in test-negative patients. Hence, we denote by
t′v and t′b the corresponding time points under BBS. With
b := tb − t′b, we denote how much earlier we obtain a
proof for a benefit, and with v := t′v − tv, we denote how
much later we obtain a proof for a value.We do not require
Table 1 Some examples for the impact of the results of one enrichment design study and/or one interaction study on the time where
the test is in use following BBS or VBS, respectively
Test number Enrichment design study Interaction design study Time interval of test use under
θˆT+ θˆT− θˆT+ BBS VBS
1 0.41 [0.11, 0.51]a –0.21 [–0.39, –0.03]a 0.57 [0.39, 0.75]a E-∞ I-∞
2 0.54 [0.29, 0.78]a 0.23 [0.01, 0.44]a 0.39 [0.17, 0.52]a E-I never
3 0.66 [0.34, 0.99]a 0.11 [–0.21, 0.43] 0.47 [0.13, 0.82]a E-∞ never
4 0.29 [0.07, 0.51]a – E-∞ never
5 – –0.32 [–0.57, –0.06]a 0.71 [0.56, 0.95]a I-∞ I-∞
6 – –0.07 [–0.43, 0.57] 0.53 [0.07, 0.99]a I-∞ never
Treatment effects are expressed as log relative risks for treatment success with 95% confidence intervals.
aLog RR significant different from 0 at the 5% level. E and I refer to the time points of the enrichment and the interaction study




test of no value
test of value
BBS
test of no value
t’b tb tv t’v
time
test not in use, all patients receive i−
test in use, i− in test negative, i+ in test positive
test not in use, all patients receive i+
Fig. 1 Relevant time points and durations when comparing BBS to
VBS for a test with θT+ > 0
these numbers to be positive, although this is likely to be
the case.
There are at least six different relevant consequences of
the choice of the strategy, which are considered in Table 2
with respect to following BBS instead of VBS. First, by
bringing a test with proven benefit into use, test-positive
patients start to benefit from i+, independent of the value
of the test. This starts in the case of BBS earlier by +b.
Second, the same applies to any harm implied by exposure
to i+, e.g., if there are safety issues. Third, as long as we
do not have detected that a test has no value, test-negative
patients will receive i− and cannot benefit from i+. The
time point of detecting and changing this is delayed by
v in the case of a BBS. Fourth, there may be harm to
patients by exposure to the diagnostic test. If the test has
a value, this means that this harm starts earlier by +b;
if the test has no value, this will happen in a period of
length  + b + v instead of never. The same argu-
ment applies to the costs implied by using the test—the
fifth consequence considered in Table 2. The monetary
costs of a test are of course independent of whether the
test has a value or is of no value. However—as pointed out
above—we may regard the costs as differing in quality, as
in the case of a test with a value these costs are inevitable
in order to improve patient outcome, whereas this is not
the case for a test with no value. However, prior to tv or
t′v, respectively, we do not know that this may be the case,
so we cannot criticize the use of these resources prior to
these time points. A sixth relevant consequence has been
pointed out by the FDA [2]: If a benefit is proven, but
the value is still unknown, there may happen off-label use
in the test-negative patients after approving i+ for test-
positive patients. This off-label use hopefully stops once it
is proven that the test has a value, i.e., that there is no clini-
cally relevant treatment effect in the test negative patients.
If the off-label use happens in all test-negative patients,
then this decreases the average outcome if the test has
a value, and it increases the average outcome if the test
has no value. If the-off label use is selective—in particu-
lar, if the continuous marker X is taken into account and
only patients with values close to the current cut point are
selected for off label use—then the average outcome may
increase even in the case of a test with no value.
In summarizing the insights we can obtain from Table 2,
let us start with looking at the first five consequences and
assuming v = 0. Then, evaluating the consequences of
using BBS instead of VBS for a single test involves only
the consequences 1), 2), 4), and 5) and reduces to a com-
parison of the gain in efficacy when applying i+ instead
of i− in test-positive patients with the harms implied in
these patients and with the harms and costs implied by
applying the test in all patients, i.e., traditional benefit-risk
and cost-benefit analyses. We have only to take in addi-
tion into account that this comparison concerns a limited
time interval of length  + b, and we have to remember
that benefit, costs, and risk should refer to all patients, not
only to test-positive ones. In particular, the benefit is given
by bT and not by θT+ . Note also that these considerations
are independent of whether the test is of value or is of no
value. In contrast, consequence 6) differs between tests of
value and tests of no value.
If v > 0, we have to take into account additional neg-
ative consequences in the case of a test with no value, as
Table 2 Six consequences of using BBS instead of VBS for a single new diagnostic test
Test has a value Test has no value
1) Test-positive patients can
benefit from i+
Starts earlier by  + b Starts earlier by  + b
2) Harm to test-positive
patients by exposure to i+
Starts earlier by  + b Starts earlier by  + b
3) Test-negative patients can
benefit from i+
Not applicable Delayed by v
4) Harm to all patients by
exposure to test
Starts earlier by  + b In a period of length  + b + v
5) Use of resources for testing
all patients
Starts earlier by  + b In a period of length  + b + v
6) Additional off-label use In a period of length  + b + v
—harm to patients probable
In a period of length  + b
—harm to patients less probable
Vach Diagnostic and Prognostic Research  (2017) 1:4 Page 7 of 9
we prolong the period where test-negative patients do not
benefit from i+, and we prolong the period of additional
costs and potential harm by application of the test in all
patients. In the case of a test with a value, we also prolong
the period of a possible and probably harmful off-label use
(Table 1).
Further aspects in comparing BBS and VBS
In evaluating the advantages and disadvantages of using
BBS or VBS, it is important to understand that  and v
can be infinite. In the “Interaction designs” section, we
have pointed out the difficulty to come to a decision about
the value of a test when θT− is close to 0. So for such a test,
it is likely that  = ∞ holds, as we will never be able
to perform a study of sufficient size. Similarly,  = ∞
holds for all tests, where we hesitate to perform stud-
ies in test-negative patients, as the clinical or biological
model suggests θT− ≤ 0. In any case,  = ∞ implies that
only under BBS test-positive patients can ever benefit from
getting i+.
The case v = ∞ means that we never perform a study
with an interaction design or an RCT in test-negative
patients as consequence of using BBS instead of VBS. This
may happen if such a study is in principle feasible, but after
establishing the benefit in an enrichment study, there is
no further incentive to perform such a study. In this case,
the basic advantage of VBS is just that we ever detect that
a test has no value and that test-negative patients then can
benefit from i+.
The choice of BBS instead of VBS may, however, not only
imply that we start to use enrichment designs earlier or
instead of interaction studies or wait longer until we start
interaction studies after performing enrichment studies. It
might also imply that tests of no value, which would never
been developed in the case of VBS, are now developed and
never detected as being of no value.
Finally, it should be noted that the strategy chosen has
also an impact on decisions about new diagnostic tests
with an existing comparator. In BBS, we have to prove the
additional benefit. In VBS, we have to require in addition
that we know that the existing comparator is of value.
In the long run, this constitutes no problem as the com-
parator could only come into use after proving its value.
However, when introducing VBS as a new principle, we
may lack such a proof for the comparator.
Superiority of benefit-based or value-based strategy
Our considerations in the previous sections suggest that
for a single test, BBS can imply a disadvantage compared
to VBS if v > 0 (and in particular, if v = ∞) or/and if
off-label use harms patients. This may be avoided by cor-
responding additional means, for example, a conditional
approval requiring to perform studies allowing a decision
on the value of the test within a certain time period and
strict restrictions on off-label use. Then, for each test,
patients will benefit from BBS compared to VBS, but at the
societal level, there is still the risk for introducing more
tests with no value. If such means are not available or
it cannot be guaranteed that they work, it is more chal-
lenging to make statements about the superiority of one
approach over the other, and further considerations are
necessary. First, for a test with θT+ ≤ 0 and θT− ≤ 0, we
expect no difference, as under both strategies we should
never start to use the test and all patients will always
receive i−. If θT+ > 0 and θT− ≤ 0, i.e., the test is of
value, BBS is of advantage. Averaging over all tests of value,
the tests with  = ∞ make the dominating contribu-
tion, as then only under BBS patients will ever benefit. If
θT− > 0 and θT+ > 0, i.e., the test is of no value, VBS
can be of advantage avoiding a delay in allowing test-
negative patients to benefit from i+. Averaging over all
tests of no value, the tests with v = ∞ and  < ∞
make the dominating contribution, as then only under VBS
test-negative patients will ever benefit. So roughly speak-
ing, we have to find out whether there will be more tests
of value with  = ∞ or more tests of no value with
v = ∞ and  < ∞, if we assume that eT+− − e−−
and e++ − eT+− are on average of the same magnitude
in these two groups. These frequencies reflect the pro-
portion of tests of value and of no value among all tests,
the frequency of not performing interactions studies or
performing interactions studies with insufficient power to
demonstrate θT− ≤ 0 among tests of value, and the fre-
quency of not performing interactions studies for tests of
no value after successfully performing enrichment stud-
ies, even if this is feasible and would have been done if no
enrichment study has been performed. Hence, the deci-
sion about the superiority of each strategy dependsmainly
on the research practice, and how a country can influ-
ence it in general and by the chosen strategy. A conditional
approval mentioned above is one example for how to take
a direct influence. In general, from a societal perspec-
tive, it is desirable that interaction studies are performed
to sort out tests of no value. However, interaction stud-
ies require to randomize also the test-negative patients,
even if there is little hope that any of these patients can
benefit from i+, and—as i+ is typically a new therapy
with unexplored safety profile—some likelihood for harm.
Hence, societal interests may be in conflict with patient
interests.
Discussion
Our considerations demonstrate that it is useful and nec-
essary to distinguish between the value and the benefit of a
diagnostic test. The two perspectives have a direct impact
on the analysis and interpretation of diagnostic studies,
requiring the use of different approaches. Equaling value
with benefit should be avoided.
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Benefit and value are also fundamental corner stones in
the strategies countries can choose to control the process
of bringing diagnostic tests into use. The considerations
of the IQWiG in its methodological guideline suggest that
the IQWiG is favoring a value-based strategy. The consid-
erations of the FDA suggest that the FDA can see some
danger in such a strategy and that it favors a modified
benefit-based strategy in the sense that even in the case
of a proven benefit, they want to take a look at a rough
estimate of θT− . Such a modification does not change the
considerations of this paper fundamentally, as also under
such a strategy a test might be brought into use without
having a proof for its value, and the benefit for the test-
positive patients may be delayed, if we hesitate to bring it
into use when we have a proof for this benefit. It will be of
interest to see which options other countries will choose.
The question about superiority of a benefit-based or
a value-based strategy cannot be answered in general. It
depends on the research practice and the means a coun-
try has to influence the research practice. Interactions
studies are desirable from a societal perspective, but not
necessarily from a patient perspective.
Our considerations are only based on logical arguments
and do not involve empirical data. Hence, the basic lim-
itation of the paper may result from wrong arguments
or from overlooking arguments. We could demonstrate
that actually many different issues make a contribution
to the discussion about the advantages and disadvantages
of the two strategies. Hence, it is desirable to continue
this discussion in order to identify wrong or overlooked
arguments.
We would finally like to mention four further
limitations:
1) We assume in our considerations that hypothesis
tests never fail. The impact of the type I error on the
strategies is not taken into account. In particular, we
ignored that tests with θT+ ≤ 0may be erroneously
regarded as having a benefit.
2) We also ignored the case θT− > 0 and θT+ ≤ 0, i.e.,
tests with a value but an incorrect expectation about
which patient group will benefit from the
intervention.
3) We also ignored the possibility that during the
development of a test, we may obtain evidence for
θall > 0, e.g., from an RCT comparing i+ with i−
without applying the test.
4) We considered only single studies as evidence base.
In reality, several studies may be available, and we
have to use meta analytical techniques.
Conclusions
The benefit and the value of a diagnostic test are two dif-
ferent concepts which need to be distinguished. Decisions
to bring a test into use can be based on a proof of its ben-
efit or a proof of its value. The superiority of these two
strategies is highly depending on the research practice and
its interaction with the strategies. Benefit-based strategies
are preferable if the risk of off-label use and of delayed
decisions on the value of a test can be limited.
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